Behind the scenes of a zebra exam at the North Carolina Zoo
In today's Zoo Filez, FOX8's Shannon Smith takes us behind the scenes to show us what happens during one of those exams.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
FDA Issues Most Serious Risk Level for Cookie Recall
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) has issued its highest risk warning after a California-based company recalled cookies due to potential undeclared allergens. Jalux Americas, Inc, doing business as issued a voluntary recall on July 14 for multiple units of its L'espoir cookies because of undeclared milk, and its Drycapot cookies because of undeclared tree nuts (almond and macadamia nuts). The FDA has now classified the recall as Class I, its most serious category. On its website, the FDA states a Class I is "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death." Newsweek approached Jalux Americas, Inc. via an email outside of office hours for an updated statement. Why it Matters In its original announcement posted on the FDA's website, Jalux Americas, Inc. said that "people who have an allergy or severe sensitivity to milk and/or tree nuts (almond and macadamia nuts) run the risk of serious or life-threatening allergic reaction if they consume these products." A stock image of a split cookie. The FDA has issued a Class I classification, its highest risk category, after California-based Jalux Americas, Inc. initiated a recall of cookie products A stock image of a split cookie. The FDA has issued a Class I classification, its highest risk category, after California-based Jalux Americas, Inc. initiated a recall of cookie products Gavin Woodruff/iStock / Getty Images Plus Food allergies are a significant health concern in the United States, with milk and tree nuts among the nine major food allergens identified under federal law. The others are milk, eggs, fish, crustacean shellfish, peanuts, wheat, soybeans, and sesame. Allergies are an immune system's response to a substance. Allergic reactions can vary in severity from coughing and a runny nose to a life-threatening reaction known as anaphylaxis. According to the CDC's National Center for Health Statistics, almost 6 percent of U.S. adults and children have a food allergy. What To Know The recall, announced on July 14, 2025, affects: L'espoir cookies (32 units, UPC: 4 942737 200147, code: L4FN, best before 09/26/2025) for undeclared milk Drycapot cookies (28 units, UPC: 4 942737 210191, code: D4FN, best before 09/26/2025) for undeclared tree nuts (almond and macadamia nut) The products were distributed in California, Illinois, and Washington and sold exclusively at retail locations in Torrance, CA, and San Jose, CA, Arlington Heights, IL; and Lynnwood, WA. The L'espoir cookies were on sale from May 26 to June 30, 2025, and the Drycapot cookies from May 31 to June 30, 2025. No online sales occurred. Product images released by Jalux Americas, the FDA alongside a product recall of L'espoir Brand L'espoir cookies and L'espoir Brand Drycapot cookies Product images released by Jalux Americas, the FDA alongside a product recall of L'espoir Brand L'espoir cookies and L'espoir Brand Drycapot cookies Jalux Americas, Inc./FDA Jalux Americas, Inc. said the recall was "initiated after it was discovered during an inventory audit that L'espoir product containing Milk and the Drycapot product containing Tree Nuts were inadvertently distributed in packaging that did not reveal the presence of those allergens." As of July 17, no illnesses have been reported. In an earlier statement provided to Newsweek, Jalux Americas, Inc. said: "Those who have allergies to the ingredients that were inadvertently undeclared on the labels should refrain from consuming the products and return them to the store where they purchased for a full refund." The company added: "As part of our preventive measures, our supplier partner has added a step at their manufacturing facility to verify that the product matches the label after it is applied, and to record this verification in the production log. Our supplier partner will also reinforce allergy and manufacturing procedure training at the facility." The company further stated, "At the retail store level, we will strengthen our checks during stocking to ensure there are no discrepancies between products and labels, not just for the manufacturer of the recalled products but across all items. We would like to clarify that we have thus far not received any inquiries from consumers regarding this matter." The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." What Happens Next Consumers who have purchased L'espoir L4FN and Drycapot D4FN products with the best before date of 09/26/2025 are urged to return it to the place of purchase for a full refund.
Associated Press
an hour ago
- Associated Press
Healthcare Triangle, Inc. Announces 1-for-249 Reverse Stock Split as Part of Nasdaq Compliance Plan
PLEASANTON, CALIF. - July 29, 2025 ( NEWMEDIAWIRE ) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ('HCTI' or the 'Company'), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industry, today announced that it will effect a 1-for-249 reverse stock split of its common stock. The reverse stock split will become effective at 12:01 a.m. Eastern Time on Friday, August 1, 2025, and the Company's common stock will commence trading on the Nasdaq Capital Market on a post-split basis at the opening of the market on August 1, 2025, pending confirmation by the Depository Trust Company and the Nasdaq. The Company's common stock will continue to trade on the Nasdaq Capital Market under the Company's existing trading symbol, 'HCTI,' and a new CUSIP number 42227W 306 has been assigned as a result of the reverse stock split. The Company expects that the reverse stock split, which was approved by the Company's stockholders in a special meeting of Stockholders held on February 26, 2025, will increase the price per share of the Company's common stock, and is part of the Company's strategy to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market. At the effective time of the reverse stock split, each two hundred forty-nine (249) shares of the Company's issued and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.00001 per share or the total number of authorized shares. The reverse stock split will reduce the Company's number of shares outstanding common stock from approximately 1,452,124,283 shares to approximately 5,831,850 shares. No fractional shares of common stock will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to receive a fractional share will be rounded up at a participant level in lieu thereof. Stockholders of record as of August 1st, 2025, will be receiving information regarding their share ownership following the reverse stock split from the Company's transfer agent, VStock Transfer, LLC. VStock Transfer can be reached at (212) 828 8436. Additional information about the reverse stock split can be found in the Company's definitive information statement on Schedule 14C, filed with the U.S. Securities and Exchange Commission (the 'SEC') on March 17, 2025, and available free of charge at the SEC's website About Healthcare Triangle Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. For more information, visit Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate.' The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report filed with the SEC on March 31, 2025, previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Investor Contact 1-800-617-9550 [email protected]
Medscape
5 hours ago
- Medscape
Empaveli Approved for C3G and Primary IC-MPGN
The FDA has approved pegcetacoplan (Empaveli, Apellis Pharmaceuticals, Inc.) for the treatment of C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older. C3G and primary IC-MPGN are rare kidney diseases affecting approximately 5000 people in the US, particularly adolescents or young adults. They often lead to kidney failure requiring dialysis or kidney transplant. In the recently released Phase 3 VALIAN Trial 52-week results, patients receiving pegcetacoplan achieved and maintained a significant reduction in proteinuria over baseline, with a mean urine protein-to-creatinine ratio change at week 26 of -68.1% and at week 52 of -67.2%. In addition, the pegcetacoplan group showed a reduction in estimated glomerular filtration rate levels of -1.2 mL/min/1.73 m2 at week 26 and -3.7 mL/min/1.73 m2 at week 52. The most common adverse reactions were infusion site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea, according to a company press release. The product will carry a black box warning stating, 'Empaveli, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. 'Because of the risk of serious infections caused by encapsulated bacteria, Empaveli is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.' Kathleen Dallessio is the Senior Editor for Diabetes & Endocrinology and Nephrology at Medscape Medical News.
